Kairos Pharma Ltd [AMEX: KAPA] stock went on an upward path that rose over 4.44% on Tuesday, amounting to a one-week price increase of more than 14.63%.
Over the last 12 months, KAPA stock dropped by -7.24%. The one-year Kairos Pharma Ltd stock forecast points to a potential upside of 83.07. The average equity rating for KAPA stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $29.24 million, with 17.74 million shares outstanding and 8.77 million shares in the current float. Compared to the average trading volume of 5.18M shares, KAPA stock reached a trading volume of 10350102 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Kairos Pharma Ltd [KAPA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KAPA shares is $8.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KAPA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 4.17, with the Price to Cash per share for the same quarter was set at 0.15.
KAPA Stock Performance Analysis:
Kairos Pharma Ltd [KAPA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.63. With this latest performance, KAPA shares gained by 53.36% in over the last four-week period, additionally plugging by 30.56% over the last 6 months – not to mention a drop of -7.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KAPA stock in for the last two-week period is set at 71.38, with the RSI for the last a single of trading hit 0.1165, and the three-weeks RSI is set at 0.1150 for Kairos Pharma Ltd [KAPA]. The present Moving Average for the last 50 days of trading for this stock 0.9542, while it was recorded at 1.2800 for the last single week of trading, and 1.1080 for the last 200 days.
Kairos Pharma Ltd (KAPA) Capital Structure & Debt Analysis
According to recent financial data for Kairos Pharma Ltd. ( KAPA), the Return on Equity (ROE) stands at -281.84%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -122.32%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Kairos Pharma Ltd’s Return on Invested Capital (ROIC) is -78.56%, showcasing its effectiveness in deploying capital for earnings.
Kairos Pharma Ltd (KAPA) Efficiency & Liquidity Metrics
Based on Kairos Pharma Ltd’s (KAPA) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Kairos Pharma Ltd (KAPA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Kairos Pharma Ltd. (KAPA) effectively leverages its workforce, generating an average of -$1177500.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 7.16% and a Quick Ratio of 7.16%, indicating strong ability to cover short-term liabilities.
KAPA Stock EPS
With the latest financial reports released by the company, Kairos Pharma Ltd posted -0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.02/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.08. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KAPA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Kairos Pharma Ltd go to -29.25%.
Kairos Pharma Ltd [KAPA] Institutonal Ownership Details
There are presently around $5.37%, or 8.72%% of KAPA stock, in the hands of institutional investors.
